Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kristen Klarin

Physician Assistant Frisco, TX Physician Assistant

NPI 1083133474 CMS profile 10558880

5375 Coit Rd Ste 130, Frisco, TX 75035

Open in the dashboard

General payments

$12,456

633 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kristen Klarin of Frisco, TX is reported in the CMS Open Payments database as having received $12,456 across 633 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,627 162
2024 General $2,946 148
2023 General $1,735 85
2022 General $2,270 124
2021 General $1,879 114

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kristen Klarin
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Kristen Klarin were reported at $3,627. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Kristen Klarin Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,879 $132 $37–$438 $132
2022 $2,270 $155 $48–$522 $149
2023 $1,735 $167 $52–$557 $160
2024 $2,946 $178 $55–$600 $164
2025 $3,627 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,732 115 payments
  2. UCB, Inc. $665 27 payments
  3. Biogen, Inc. $631 31 payments
  4. Teva Pharmaceuticals USA, Inc. $493 29 payments
  5. Lilly USA, LLC $454 19 payments
  6. Genentech USA, Inc. $426 18 payments
  7. Novartis Pharmaceuticals Corporation $377 23 payments
  8. Alexion Pharmaceuticals, Inc. $369 19 payments
  9. ACADIA Pharmaceuticals Inc $353 17 payments
  10. SK Life Science, Inc. $327 12 payments
  11. Other $6,627 323 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $12,399 632 payments
  2. Education $57 1 payment
Products named General payments · program years 2021–2025
  1. QULIPTA $916 66 payments
  2. UBRELVY $687 52 payments
  3. BOTOX $480 30 payments
  4. NURTEC ODT $406 24 payments
  5. Austedo XR $401 23 payments
  6. AIMOVIG $333 16 payments
  7. Briviact $311 12 payments
  8. ZEPOSIA $306 17 payments
  9. TYSABRI $294 13 payments
  10. ZEMBRACE SYMTOUCH $278 13 payments
  11. Other $9,331 461 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

633 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record